JavaScript is disabled in your browser. Please enable JavaScript to view this website.
AB100662

Human VEGF ELISA Kit

Be the first to review this product! Submit a review

|

(41 Publications)

Human VEGF ELISA Kit is a sandwich ELISA designed to quantify Human VEGF with a sensitivity of 10 pg/mL.

- Colorimetric sandwich ELISA - 450 nm readout - works on any plate reader
- Wide dynamic range - quantifies 8.23 - 6000 pg/mL
- Cited in over 30 publications

View Alternative Names

VEGF, VEGFA, L-VEGF, Vascular permeability factor, VPF

4 Images
Sandwich ELISA - Human VEGF ELISA Kit (AB100662)
  • sELISA

Unknown

Sandwich ELISA - Human VEGF ELISA Kit (AB100662)

Representative standard curve using ab100662

Sandwich ELISA - Human VEGF ELISA Kit (AB100662)
  • sELISA

Unknown

Sandwich ELISA - Human VEGF ELISA Kit (AB100662)

Representative standard curve using ab100662

Sandwich ELISA - Human VEGF ELISA Kit (AB100662)
  • sELISA

Lab

Sandwich ELISA - Human VEGF ELISA Kit (AB100662)

Curves showing concentrations huVEGF165 in NIBSC 02/286 using ab100662 VEGF human

Sandwich ELISA - Human VEGF ELISA Kit (AB100662)
  • sELISA

Lab

Sandwich ELISA - Human VEGF ELISA Kit (AB100662)

VEGF measured in biological fluids showing quantity (pg) per milliliter of sample tested

Key facts

Detection method

Colorimetric

Sample types

Plasma, Cell culture supernatant, Serum

Reacts with

Human

Assay type

Sandwich (quantitative)

Sensitivity

< 10 pg/mL

Range

8.23 - 6000 pg/mL

Assay Platform

Microplate

Reactivity data

{ "title": "Reactivity Data", "filters": { "stats": ["", "Reactivity", "Dilution Info", "Notes"] }, "values": { "sELISA": { "reactivity":"TESTED_AND_REACTS", "dilution-info":"", "notes":"<p></p>" } } }

Product details

Human VEGF ELISA Kit ab100662 is a sandwich ELISA to measure Human VEGF in serum, plasma, cell culture supernatant with a sensitivity of 10 pg/ml.

How the assay works

This assay employs an antibody specific for Human VEGF coated on a 96-well plate. Standards and samples are pipetted into the wells and VEGF present in a sample is bound to the wells by the immobilized antibody. The wells are washed and biotinylated anti-Human VEGF antibody is added. After washing away unbound biotinylated antibody, HRP-conjugated streptavidin is pipetted to the wells. The wells are again washed, a TMB substrate solution is added to the wells and color develops in proportion to the amount of VEGF bound. The Stop Solution changes the color from blue to yellow, and the intensity of the color is measured at 450 nm.

Assay Specificity

Our ELISA kits are rigorously validated to ensure the highest level of consistency and reproducibility. Please check the protocol booklet for more details

Human VEGF ELISA Kit ab100662 protocol summary

1. Add standard or sample to each well used. Incubate at room temperature
2. Wash and add prepared biotinylated antibody to each well. Incubate at room temperature.
3. Wash and add prepared streptavidin solution. Incubate at room temperature.
4. Add TMB Development Solution to each well. Incubate at room temperature.
5. Add Stop Solution to each well. Read at 450nm immediately.

Optimization may be required with urine samples.

Recovery

[ { "sample": "Cell culture supernatant", "range": "92 - 113 %", "average": "= 103.5" }, { "sample": "Serum", "range": "92 - 115 %", "average": "= 104.4" }, { "sample": "Plasma", "range": "93 - 114 %", "average": "= 105.7" } ]

What's included?

{ "values": { "1x96Tests": { "sellingSize": "1 x 96 Tests", "publicAssetCode":"ab100662-1x96Tests", "assetComponentDetails": [ { "size":"1 x 25 mL", "name":"20X Wash Buffer", "number":"AB100662-CMP03", "productcode":"" }, { "size":"1 x 8 mL", "name":"Stop Solution", "number":"AB100662-CMP07", "productcode":"" }, { "size":"1 x 30 mL", "name":"Assay Diluent A", "number":"AB100662-CMP05", "productcode":"" }, { "size":"1 x 15 mL", "name":"5X Assay Diluent B", "number":"AB100662-CMP06", "productcode":"" }, { "size":"1 x 200 µL", "name":"300X HRP-Streptavidin Concentrate", "number":"AB100662-CMP04", "productcode":"" }, { "size":"1 x 1 Unit", "name":"VEGF Microplate (12 x 8 wells)", "number":"AB100662-CMP01", "productcode":"" }, { "size":"2 x 1 Vial", "name":"Recombinant Human VEGF Standard (lyophilized)", "number":"AB100662-CMP02", "productcode":"" }, { "size":"1 x 12 mL", "name":"TMB One-Step Substrate Reagent", "number":"AB100662-CMP08", "productcode":"" }, { "size":"2 x 1 Vial", "name":"Biotinylated anti-Human VEGF", "number":"AB100662-CMP09", "productcode":"" } ] } } }

Properties and storage information

Shipped at conditions
Blue Ice
Appropriate short-term storage conditions
-20°C
Appropriate long-term storage conditions
-20°C
Storage information
-20°C

Supplementary information

This supplementary information is collated from multiple sources and compiled automatically.

Vascular endothelial growth factor A (VEGFA) also known as VEGF or vascular permeability factor (VPF) is a protein that plays a central role in angiogenesis as well as in the growth of blood vessels. The molecular weight of VEGFA varies depending on the isoform typically ranging from 34 to 42 kDa. VEGFA is expressed in many tissues including fibroblasts macrophages endothelial cells and platelets. Its expression levels can increase in response to stimuli like hypoxia or inflammatory cytokines. VEGFA is an important target in research for therapies related to vascular diseases and cancer.
Biological function summary

VEGFA functions by promoting the proliferation and migration of vascular endothelial cells. It operates both as a homodimer and as part of complex signaling cascades interacting with VEGF receptors on cell surfaces to trigger downstream signals for angiogenesis. This includes endothelial cell growth migration and the new blood vessel formation process. VEGFA's activity is important for physiological processes such as wound healing and embryonic development and it also contributes to pathological conditions through its unregulated expression in diseases.

Pathways

Many processes involve VEGFA including the PI3K/AKT pathway and the MAPK/ERK pathway. These pathways regulate cell survival growth and differentiation. Other proteins like PLGF (placenta growth factor) and VEGFB often accompany VEGFA in these pathways aiding in distinct but overlapping roles. These interactions are transmitted through binding to VEGF receptors such as VEGFR-1 and VEGFR-2 subsequently activating various signaling cascades necessary for cellular and tissue homeostasis.

VEGFA relates to cancer and age-related macular degeneration among others. In cancer overexpression of VEGFA can lead to excessive angiogenesis supplying blood to tumors and facilitating tumor growth. In age-related macular degeneration upregulation of VEGFA contributes to the progression of the disease by promoting the formation of abnormal blood vessels under the retina. Anti-VEGFA therapies such as anti-VEGF antibodies (e.g. bevacizumab) can target these overexpressed pathways. VEGFA interacts with other proteins like HIF-1α which regulates its expression under hypoxia a common condition in tumors.

Product protocols

Target data

N-VEGF. Participates in the induction of key genes involved in the response to hypoxia and in the induction of angiogenesis such as HIF1A (PubMed : 35455969). Involved in protecting cells from hypoxia-mediated cell death (By similarity).. VEGFA. Growth factor active in angiogenesis, vasculogenesis and endothelial cell growth (PubMed : 34530889). Induces endothelial cell proliferation, promotes cell migration, inhibits apoptosis and induces permeabilization of blood vessels. Binds to the FLT1/VEGFR1 and KDR/VEGFR2 receptors, heparan sulfate and heparin. Binds to the NRP1/neuropilin-1 receptor. Binding to NRP1 initiates a signaling pathway needed for motor neuron axon guidance and cell body migration, including for the caudal migration of facial motor neurons from rhombomere 4 to rhombomere 6 during embryonic development (By similarity). Also binds the DEAR/FBXW7-AS1 receptor (PubMed : 17446437).. Isoform VEGF165B. Binds to the KDR receptor but does not activate downstream signaling pathways, does not activate angiogenesis and inhibits tumor growth.
See full target information VEGFA

Publications (41)

Recent publications for all applications. Explore the full list and refine your search

Cells 14: PubMed40214480

2025

Platelet-Rich Plasma Extract Derived from Animals Shows Potential in Promoting Wound Healing and Suppressing Inflammatory Response in Skin Cells.

Applications

Unspecified application

Species

Unspecified reactive species

Zheng-Qi Wang,Queenie Wing-Sze Lai,Xiong Gao,Qi-Yun Wu,Tina Ting-Xia Dong,Karl Wah-Keung Tsim

Journal of cannabis research 6:43 PubMed39707578

2024

Evaluation of the metabolic activity, angiogenic impacts, and GSK-3β signaling of the synthetic cannabinoid MMB-2201 on human cerebral microvascular endothelial cells.

Applications

Unspecified application

Species

Unspecified reactive species

Laith Naser Al-Eitan,Saif Zuhair Alahmad,Sufyan Ali Ajeen,Ahmad Younis Altawil,Iliya Yacoub Khair,Hana Salah Abu Kharmah,Mansour Abdullah Alghamdi

Obstetric medicine 18:75-81 PubMed39553185

2024

Vascular endothelial growth factor/platelet ratio as a potential biomarker for preeclampsia: A study of angiogenic markers in Pakistani patients.

Applications

Unspecified application

Species

Unspecified reactive species

Feriha Fatima Khidri,Yar Muhammad Waryah,Roohi Nigar,Zaib-Un-Nisa Mughal,Jawaid Ahmed Zai,Ali Raza Rao,Ikram Din Ujjan,Ali Muhammad Waryah

Molecular carcinogenesis 63:2254-2268 PubMed39171838

2024

Quercetin inhibits endothelial & hepatocellular carcinoma cell crosstalk via reducing extracellular vesicle-mediated VEGFR2 mRNA transfer.

Applications

Unspecified application

Species

Unspecified reactive species

Wei Xiong,Bo Zheng,Di Liu,Mo Pu,Shijie Zhou,Ying Deng

EXCLI journal 23:634-654 PubMed38887393

2024

Exosomes derived from colorectal cancer cells take part in activation of stromal fibroblasts through regulating PHLPP isoforms.

Applications

Unspecified application

Species

Unspecified reactive species

Fatemeh Khaloozadeh,Ehsan Razmara,Fatemeh Asgharpour-Babayian,Alireza Fallah,Reihaneh Ramezani,Fatemeh Rouhollah,Sadegh Babashah

Iranian journal of basic medical sciences 27:304-310 PubMed38333752

2024

Assessment of the proliferative and angiogenic effects of the synthetic cannabinoid (R)-5-fluoro ADB on human cerebral microvascular endothelial cells.

Applications

Unspecified application

Species

Unspecified reactive species

Laith Naser Al-Eitan,Saif Zuhair,Iliya Yacoub Khair,Mansour Abdullah Alghamdi

Cells 12: PubMed38067126

2023

An Exosome-Rich Conditioned Medium from Human Amniotic Membrane Stem Cells Facilitates Wound Healing via Increased Reepithelization, Collagen Synthesis, and Angiogenesis.

Applications

Unspecified application

Species

Unspecified reactive species

Chan Ho Noh,Sangryong Park,Hye-Rim Seong,Ah-Young Lee,Khan-Erdene Tsolmon,Dongho Geum,Soon-Cheol Hong,Tae Myoung Kim,Ehn-Kyoung Choi,Yun-Bae Kim

Glycobiology 33:1155-1171 PubMed37847613

2023

Targeting aberrant sialylation and fucosylation in prostate cancer cells using potent metabolic inhibitors.

Applications

Unspecified application

Species

Unspecified reactive species

Margarita Orozco-Moreno,Eline A Visser,Kirsty Hodgson,Agnes L Hipgrave Ederveen,Kayla Bastian,Emily Archer Goode,Özden Öztürk,Johan F A Pijnenborg,Nienke Eerden,Sam J Moons,Emiel Rossing,Ning Wang,Noortje de Haan,Christian Büll,Thomas J Boltje,Jennifer Munkley

Cancers 15: PubMed37173995

2023

Regulation of VEGFR2 and AKT Signaling by Musashi-2 in Lung Cancer.

Applications

Unspecified application

Species

Unspecified reactive species

Igor Bychkov,Iuliia Topchu,Petr Makhov,Alexander Kudinov,Jyoti D Patel,Yanis Boumber

International journal of oncology 62: PubMed36660950

2023

Extracellular vesicle‑mediated miR‑126‑3p transfer contributes to inter‑cellular communication in the liver tumor microenvironment.

Applications

Unspecified application

Species

Unspecified reactive species

Anuradha Moirangthem,Piyush Gondaliya,Irene K Yan,Adil Ali Sayyed,Julia Driscoll,Tushar Patel
View all publications
websiteProtocolBooklet
en

Product promise

We are committed to supporting your work with high-quality reagents, and we're here for you every step of the way. In the unlikely event that one of our products does not perform as expected, you're protected by our Product Promise.
For full details, please see our Terms & Conditions

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com